Gemcitabine + Cisplatin
Treatment for Gallbladder And Biliary Tract Cancer
Typical Dosage: Gemcitabine 1000 mg/m² IV (day 1, 8) + Cisplatin 25 mg/m² IV (day 1) every 21 days
Effectiveness
55%
Safety Score
25%
Clinical Trials
41
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Gemcitabine 1000 mg/m² IV (day 1, 8) + Cisplatin 25 mg/m² IV (day 1) every 21 days
Time to Effect
1-2 months
Treatment Duration
Typically 6-8 cycles (4-6 months)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
4(Treat 4 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10,000
Monitoring:$20,000
Side Effect Mgmt:$15,000
Total Annual:$45,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$50,000/QALY
QALYs Gained
0.7
Outcome-Based Costs
Cost per Responder
$180,000
Cost per Remission
$2,250,000
Comparison vs Gemcitabine monotherapy
Cost Difference
+$7,500/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
Gemcitabine + Cisplatin Outcomes
for Gallbladder And Biliary Tract Cancer
Efficacy Outcomes
Overall Effectiveness
+55%
Response Rate
+25%
Remission Rate
+2%
Common Side Effects
Myelosuppression
+60%
Fatigue
+60%
Nausea/Vomiting
+40%
Peripheral neuropathy
+30%
Nephrotoxicity
+15%
Sources:
Active Clinical Trials
5 active trials recruiting for Gemcitabine + Cisplatin in Gallbladder And Biliary Tract Cancer
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
NCT02151084ACTIVE NOT RECRUITINGPHASE2
57 participants
INTERVENTIONAL
Toronto, Canada
Started: Nov 1, 2014
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253RECRUITINGPHASE3
1.1K participants
INTERVENTIONAL
Birmingham, United States +161 more
Started: Dec 4, 2025
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575RECRUITINGPHASE3
286 participants
INTERVENTIONAL
Duarte, United States +182 more
Started: Jul 19, 2024
Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
NCT04308174ACTIVE NOT RECRUITINGPHASE2
45 participants
INTERVENTIONAL
Seoul, South Korea
Started: May 20, 2020
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
NCT02170090ACTIVE NOT RECRUITINGPHASE3
789 participants
INTERVENTIONAL
Bankstown, Australia +66 more
Started: Apr 1, 2014
Completed Clinical Trials
11 completed trials for Gemcitabine + Cisplatin in Gallbladder And Biliary Tract Cancer
Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer
NCT00123825COMPLETEDPHASE2
30 participants
INTERVENTIONAL
Boston, United States +2 more
Started: Jul 1, 2002
ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer
NCT01242605COMPLETEDPHASE1
13 participants
INTERVENTIONAL
London, United Kingdom +2 more
Started: Feb 1, 2012
Pembrolizumab in Biliary Tract Cancer
NCT03260712COMPLETEDPHASE2
50 participants
INTERVENTIONAL
Leipzig, Germany +6 more
Started: Jan 7, 2020
Biomarker Discovery in Patients With Advanced Biliary Tract Cancer
NCT04871321COMPLETED
119 participants
OBSERVATIONAL
Seongnam-si, South Korea
Started: Apr 14, 2021
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study
NCT04924062COMPLETEDPHASE3
158 participants
INTERVENTIONAL
Hefei, China +21 more
Started: Jul 10, 2020
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
NCT04003636COMPLETEDPHASE3
1.07K participants
INTERVENTIONAL
Birmingham, United States +184 more
Started: Sep 24, 2019
Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy
NCT00919061COMPLETEDPHASE2
39 participants
INTERVENTIONAL
New York, United States
Started: Aug 1, 2009
Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors
NCT00262769COMPLETEDPHASE3
324 participants
INTERVENTIONAL
Basingstoke, United Kingdom +24 more
Started: May 1, 2005
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
NCT02631590COMPLETEDPHASE2
24 participants
INTERVENTIONAL
Tampa, United States
Started: Jul 5, 2016
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
NCT02375880COMPLETEDPHASE1
51 participants
INTERVENTIONAL
Los Angeles, United States +8 more
Started: Jun 1, 2015
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
NCT03768414COMPLETEDPHASE3
452 participants
INTERVENTIONAL
Anchorage, United States +691 more
Started: Feb 7, 2019
Showing 20 of 41 total trials